Omega-3  ||| S:0 E:8 ||| NNP
fatty  ||| S:8 E:14 ||| NN
acids  ||| S:14 E:20 ||| NNS
in  ||| S:20 E:23 ||| IN
major  ||| S:23 E:29 ||| JJ
depressive  ||| S:29 E:40 ||| JJ
disorder  ||| S:40 E:49 ||| NN
Patients  ||| S:49 E:58 ||| NNS
with  ||| S:58 E:63 ||| IN
major  ||| S:63 E:69 ||| JJ
depressive  ||| S:69 E:80 ||| JJ
disorder  ||| S:80 E:89 ||| NNS
have  ||| S:89 E:94 ||| VBP
high  ||| S:94 E:99 ||| JJ
rates  ||| S:99 E:105 ||| NNS
of  ||| S:105 E:108 ||| IN
cardiovascular  ||| S:108 E:123 ||| JJ
disease  ||| S:123 E:131 ||| NN
and  ||| S:131 E:135 ||| CC
other  ||| S:135 E:141 ||| JJ
medical  ||| S:141 E:149 ||| JJ
comorbidity ||| S:149 E:160 ||| NN
.  ||| S:160 E:162 ||| .
Omega-3  ||| S:162 E:170 ||| FW
fatty  ||| S:170 E:176 ||| FW
acids ||| S:176 E:181 ||| FW
,  ||| S:181 E:183 ||| ,
particularly  ||| S:183 E:196 ||| RB
those  ||| S:196 E:202 ||| DT
found  ||| S:202 E:208 ||| VBN
in  ||| S:208 E:211 ||| IN
fish  ||| S:211 E:216 ||| NN
and  ||| S:216 E:220 ||| CC
seafood ||| S:220 E:227 ||| NN
,  ||| S:227 E:229 ||| ,
have  ||| S:229 E:234 ||| VBP
cardiovascular  ||| S:234 E:249 ||| JJ
health  ||| S:249 E:256 ||| NN
benefits  ||| S:256 E:265 ||| NNS
and  ||| S:265 E:269 ||| CC
may  ||| S:269 E:273 ||| MD
play  ||| S:273 E:278 ||| VB
an  ||| S:278 E:281 ||| DT
adjunctive  ||| S:281 E:292 ||| JJ
role  ||| S:292 E:297 ||| NN
in  ||| S:297 E:300 ||| IN
the  ||| S:300 E:304 ||| DT
treatment  ||| S:304 E:314 ||| NN
of  ||| S:314 E:317 ||| IN
mood  ||| S:317 E:322 ||| NN
disorders ||| S:322 E:331 ||| NNS
.  ||| S:331 E:333 ||| .
However ||| S:333 E:340 ||| RB
,  ||| S:340 E:342 ||| ,
existing  ||| S:342 E:351 ||| VBG
studies  ||| S:351 E:359 ||| NNS
on  ||| S:359 E:362 ||| IN
omega-3  ||| S:362 E:370 ||| CD
fatty  ||| S:370 E:376 ||| CD
acids  ||| S:376 E:382 ||| NNS
in  ||| S:382 E:385 ||| IN
depression  ||| S:385 E:396 ||| NNS
have  ||| S:396 E:401 ||| VBP
limitations  ||| S:401 E:413 ||| NNS
such  ||| S:413 E:418 ||| JJ
as  ||| S:418 E:421 ||| IN
small  ||| S:421 E:427 ||| JJ
sample  ||| S:427 E:434 ||| NN
sizes  ||| S:434 E:440 ||| NNS
and  ||| S:440 E:444 ||| CC
a  ||| S:444 E:446 ||| DT
wide  ||| S:446 E:451 ||| JJ
variance  ||| S:451 E:460 ||| NN
in  ||| S:460 E:463 ||| IN
study  ||| S:463 E:469 ||| NN
design ||| S:469 E:475 ||| NN
,  ||| S:475 E:477 ||| ,
and  ||| S:477 E:481 ||| CC
results  ||| S:481 E:489 ||| NNS
regarding  ||| S:489 E:499 ||| VBG
efficacy  ||| S:499 E:508 ||| NNS
are  ||| S:508 E:512 ||| VBP
mixed ||| S:512 E:517 ||| VBN
.  ||| S:517 E:519 ||| .
The  ||| S:519 E:523 ||| DT
preponderance  ||| S:523 E:537 ||| NN
of  ||| S:537 E:540 ||| IN
data  ||| S:540 E:545 ||| NNS
from  ||| S:545 E:550 ||| IN
placebo-controlled  ||| S:550 E:569 ||| JJ
treatment  ||| S:569 E:579 ||| NN
studies  ||| S:579 E:587 ||| NNS
suggests  ||| S:587 E:596 ||| VBZ
that  ||| S:596 E:601 ||| IN
omega-3  ||| S:601 E:609 ||| CD
fatty  ||| S:609 E:615 ||| CD
acids  ||| S:615 E:621 ||| NNS
are  ||| S:621 E:625 ||| VBP
a  ||| S:625 E:627 ||| DT
reasonable  ||| S:627 E:638 ||| JJ
augmentation  ||| S:638 E:651 ||| JJ
strategy  ||| S:651 E:660 ||| NN
for  ||| S:660 E:664 ||| IN
the  ||| S:664 E:668 ||| DT
treatment  ||| S:668 E:678 ||| NN
of  ||| S:678 E:681 ||| IN
major  ||| S:681 E:687 ||| JJ
depressive  ||| S:687 E:698 ||| JJ
disorder ||| S:698 E:706 ||| NN
.  ||| S:706 E:708 ||| .
More  ||| S:708 E:713 ||| JJR
research  ||| S:713 E:722 ||| NN
is  ||| S:722 E:725 ||| VBZ
necessary  ||| S:725 E:735 ||| JJ
before  ||| S:735 E:742 ||| IN
omega-3  ||| S:742 E:750 ||| CD
supplements  ||| S:750 E:762 ||| NNS
can  ||| S:762 E:766 ||| MD
be  ||| S:766 E:769 ||| VB
recommended  ||| S:769 E:781 ||| VBN
as  ||| S:781 E:784 ||| IN
monotherapy  ||| S:784 E:796 ||| NN
for  ||| S:796 E:800 ||| IN
the  ||| S:800 E:804 ||| DT
treatment  ||| S:804 E:814 ||| NN
of  ||| S:814 E:817 ||| IN
depression ||| S:817 E:827 ||| NN
.  ||| S:827 E:829 ||| .
For  ||| S:829 E:833 ||| IN
many  ||| S:833 E:838 ||| JJ
individuals  ||| S:838 E:850 ||| NNS
with  ||| S:850 E:855 ||| IN
major  ||| S:855 E:861 ||| JJ
depressive  ||| S:861 E:872 ||| JJ
disorder ||| S:872 E:880 ||| NN
,  ||| S:880 E:882 ||| ,
augmentation  ||| S:882 E:895 ||| VBG
with  ||| S:895 E:900 ||| IN
omega-3  ||| S:900 E:908 ||| CD
fatty  ||| S:908 E:914 ||| CD
acids  ||| S:914 E:920 ||| NNS
should  ||| S:920 E:927 ||| MD
be  ||| S:927 E:930 ||| VB
considered ||| S:930 E:940 ||| VBN
,  ||| S:940 E:942 ||| ,
as  ||| S:942 E:945 ||| IN
general  ||| S:945 E:953 ||| JJ
health  ||| S:953 E:960 ||| NN
benefits  ||| S:960 E:969 ||| NNS
are  ||| S:969 E:973 ||| VBP
well  ||| S:973 E:978 ||| RB
established  ||| S:978 E:990 ||| VBN
and  ||| S:990 E:994 ||| CC
adjunctive  ||| S:994 E:1005 ||| JJ
use  ||| S:1005 E:1009 ||| NN
is  ||| S:1009 E:1012 ||| VBZ
low  ||| S:1012 E:1016 ||| JJ
risk ||| S:1016 E:1020 ||| NN
.  ||| S:1020 E:1022 ||| .
